TET2 Antibody | 7731

TET2 Antibody | 7731 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: TET2 antibody was raised against an 18 amino acid peptide near the carboxy terminus of human TET2.
The immunogen is located within amino acids 1550 - 1600 of TET2.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB

Application: TET2 antibody can be used for detection of TET2 by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.

Specificiy: TET2 antibody is human and mouse reactive. At least two isoforms of TET2 are known to exist; this antibody will detect the larger isoforms. This antibody is predicted to not cross-react with TET1 and TET3.

Positive Control 1: Cat. No. 1282 - 3T3 (NIH) Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 220 kDa
Observed: 220 kDa

Validation: N/A

Isoform: N/A

Purification: TET2 antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: TET2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: TET2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.

Alternate Name: TET2 Antibody: MDS, KIAA1546, Nbla00191, Methylcytosine dioxygenase TET2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms (1) , and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia (2) . Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.